NYSE:ENFN Enfusion - ENFN Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Enfusion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $10.49 +0.34 (+3.35%) (As of 03/21/2023 12:00 AM ET) Add Compare Share Share Today's Range$10.22▼$10.6050-Day Range$10.11▼$12.1052-Week Range$7.80▼$16.76Volume283,292 shsAverage Volume457,704 shsMarket Capitalization$1.21 billionP/E RatioN/ADividend YieldN/APrice Target$12.79 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Enfusion MarketRank™ ForecastAnalyst RatingHold2.29 Rating ScoreUpside/Downside10.4% Upside$11.58 Price TargetShort InterestBearish7.06% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.11Based on 5 Articles This WeekInsider TradingSelling Shares$11.43 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.03) to $0.01 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.62 out of 5 starsComputer And Technology Sector522nd out of 601 stocksPrepackaged Software Industry179th out of 213 stocks 2.1 Analyst's Opinion Consensus RatingEnfusion has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 2 buy ratings, 3 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.58, Enfusion has a forecasted upside of 10.4% from its current price of $10.49.Amount of Analyst CoverageEnfusion has only been the subject of 4 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.06% of the float of Enfusion has been sold short.Short Interest Ratio / Days to CoverEnfusion has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Enfusion has recently decreased by 0.55%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldEnfusion does not currently pay a dividend.Dividend GrowthEnfusion does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ENFN. Previous Next 1.7 News and Social Media Coverage News SentimentEnfusion has a news sentiment score of 0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Computer and Technology companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Enfusion this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added Enfusion to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Enfusion insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,434,790.00 in company stock.Percentage Held by Insiders40.10% of the stock of Enfusion is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions49.38% of the stock of Enfusion is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Enfusion are expected to grow in the coming year, from ($0.03) to $0.01 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enfusion is -104.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Enfusion is -104.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEnfusion has a P/B Ratio of 11.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Enfusion (NYSE:ENFN) StockEnfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. It provides portfolio management system, which generates a real-time investment book of record that consists of valuation and risk tools that allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and order and execution management system that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. The company also offers accounting/general ledger system, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion analytics system, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. Enfusion Inc. was incorporated in 2021 and is headquartered in Chicago, Illinois.Read More Receive ENFN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enfusion and its competitors with MarketBeat's FREE daily newsletter. Email Address ENFN Stock News HeadlinesMarch 16, 2023 | msn.comJP Morgan Initiates Coverage of Enfusion Inc - (ENFN) with Neutral RecommendationMarch 16, 2023 | americanbankingnews.comEnfusion, Inc. (NYSE:ENFN) Receives $12.92 Consensus Price Target from BrokeragesMarch 22, 2023 | Upexi, Inc (Ad)The Stock That Is Flying Under Wall St. RadarWith The Founder OF XPO Logistics Leading The Way This Nasdaq Company is Ready and GOING!March 15, 2023 | americanbankingnews.comEnfusion (NYSE:ENFN) Receives New Coverage from Analysts at JPMorgan Chase & Co.March 15, 2023 | finance.yahoo.comWhy Enfusion Stock Surged TodayMarch 13, 2023 | americanbankingnews.comInsider Selling: Enfusion, Inc. (NYSE:ENFN) Major Shareholder Sells $11,350,000.00 in StockMarch 8, 2023 | markets.businessinsider.comBank of America Securities Keeps Their Sell Rating on Enfusion (ENFN)March 7, 2023 | markets.businessinsider.comEnfusion Up 12% On Returning To Profit In Q4March 22, 2023 | Upexi, Inc (Ad)The Stock That Is Flying Under Wall St. RadarWith The Founder OF XPO Logistics Leading The Way This Nasdaq Company is Ready and GOING!March 7, 2023 | finance.yahoo.comEnfusion, Inc. (ENFN) Q4 Earnings Match EstimatesMarch 7, 2023 | msn.comEnfusion GAAP EPS of $0.01 beats by $0.02, revenue of $40.52M beats by $0.52MMarch 6, 2023 | msn.comEnfusion's Earnings: A PreviewFebruary 9, 2023 | finance.yahoo.comEnfusion Announces Date of Fourth Quarter and Full Year 2022 ResultsJanuary 23, 2023 | finance.yahoo.comWe Think Enfusion (NYSE:ENFN) Can Easily Afford To Drive Business GrowthJanuary 11, 2023 | finance.yahoo.comEnfusion Names Michael Spellacy as Board Chair and Non-Executive DirectorJanuary 3, 2023 | msn.comEnfusion stock jumps after Morgan Stanley upgrades to OverweightDecember 27, 2022 | finance.yahoo.comEnfusion (NYSE:ENFN) shareholders have endured a 55% loss from investing in the stock a year agoDecember 22, 2022 | finance.yahoo.comEnfusion Names Oleg Movchan as Chief Executive OfficerDecember 21, 2022 | benzinga.comLooking Into Enfusion's Return On Capital EmployedDecember 19, 2022 | msn.comEnfusion brings on Shift4 Payments' Brad Herring as CFODecember 1, 2022 | seekingalpha.comEnfusion: Cloud-Native Solution To Disrupt Legacy ProvidersNovember 30, 2022 | finance.yahoo.comEnfusion Welcomes New Addition to Board of DirectorsNovember 29, 2022 | msn.comPeering Into Enfusion's Recent Short InterestNovember 29, 2022 | finance.yahoo.comEnfusion CFO Stephen Dorton resigns from the business software makerNovember 28, 2022 | finance.yahoo.comEnfusion Announces Resignation of Chief Financial OfficerNovember 17, 2022 | benzinga.comChief Revenue Officer of Enfusion Makes $355K SaleNovember 17, 2022 | benzinga.comEnfusion Chief Technology Officer Sold $167K In Company StockSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ENFN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enfusion and its competitors with MarketBeat's FREE daily newsletter. Email Address ENFN Company Calendar Last Earnings3/07/2023Today3/21/2023Next Earnings (Estimated)5/11/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Prepackaged software Sub-IndustryN/A SectorComputer and Technology Current SymbolNYSE:ENFN CUSIPN/A CIK1868912 Webwww.enfusion.com Phone312-253-9800FaxN/AEmployees1,006Year FoundedN/APrice Target and Rating Average Stock Price Forecast$11.58 High Stock Price Forecast$14.00 Low Stock Price Forecast$9.50 Forecasted Upside/Downside+21.9%Consensus RatingHold Rating Score (0-4)2.29 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,650,000.00 Net Margins-4.90% Pretax Margin-8.11% Return on Equity3.80% Return on Assets3.37% Debt Debt-to-Equity RatioN/A Current Ratio5.57 Quick Ratio5.57 Sales & Book Value Annual Sales$150.35 million Price / Sales8.04 Cash FlowN/A Price / Cash FlowN/A Book Value$0.91 per share Price / Book11.53Miscellaneous Outstanding Shares115,270,000Free Float69,048,000Market Cap$1.21 billion OptionableNot Optionable Beta0.49 Key ExecutivesMr. Oleg Movchan (Age 49)CEO & Director Mr. Stephen MalherbeManaging PartnerMr. Bradley Herring (Age 52)Chief Financial Officer Mr. Michael BerryChief Operating OfficerMr. Daniel Groman (Age 34)Chief Technology Officer Mr. Brian MurphyInvestorMs. Lorelei M. Skillman (Age 53)Chief Marketing & Communications Officer Ms. Bronwen Bastone (Age 50)Chief People Officer Mr. Kabir KohliMD of Managed Services Solutioning & Global Head of Client ServicesMr. Joseph DefeoGlobal Head of Managed Services ProductionMore ExecutivesKey CompetitorsAvid TechnologyNASDAQ:AVIDDoceboNASDAQ:DCBOZuoraNYSE:ZUOEverbridgeNASDAQ:EVBGKingsoft CloudNASDAQ:KCView All CompetitorsInsiders & InstitutionsDan GromanSold 3,877 sharesTotal: $42,414.38 ($10.94/share)Stephen MalherbeSold 1,000,000 sharesTotal: $11.35 M ($11.35/share)Rockefeller Capital Management L.P.Bought 1,000 shares on 3/6/2023Ownership: 0.011%Alliancebernstein L.P.Sold 1,334,772 shares on 2/16/2023Ownership: 0.951%State of WyomingBought 8,343 shares on 2/16/2023Ownership: 0.008%View All Insider TransactionsView All Institutional Transactions ENFN Stock - Frequently Asked Questions Should I buy or sell Enfusion stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Enfusion in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ENFN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ENFN, but not buy additional shares or sell existing shares. View ENFN analyst ratings or view top-rated stocks. What is Enfusion's stock price forecast for 2023? 6 Wall Street research analysts have issued 12-month target prices for Enfusion's shares. Their ENFN share price forecasts range from $9.50 to $14.00. On average, they expect the company's share price to reach $11.58 in the next twelve months. This suggests a possible upside of 10.4% from the stock's current price. View analysts price targets for ENFN or view top-rated stocks among Wall Street analysts. How have ENFN shares performed in 2023? Enfusion's stock was trading at $9.67 on January 1st, 2023. Since then, ENFN stock has increased by 8.5% and is now trading at $10.49. View the best growth stocks for 2023 here. Are investors shorting Enfusion? Enfusion saw a drop in short interest in February. As of February 15th, there was short interest totaling 1,810,000 shares, a drop of 18.5% from the January 31st total of 2,220,000 shares. Based on an average daily volume of 372,900 shares, the short-interest ratio is presently 4.9 days. Currently, 7.1% of the company's stock are sold short. View Enfusion's Short Interest. When is Enfusion's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023. View our ENFN earnings forecast. How were Enfusion's earnings last quarter? Enfusion, Inc. (NYSE:ENFN) announced its earnings results on Tuesday, March, 7th. The company reported $0.01 earnings per share (EPS) for the quarter. The business earned $40.52 million during the quarter, compared to the consensus estimate of $39.88 million. Enfusion had a negative net margin of 4.90% and a positive trailing twelve-month return on equity of 3.80%. What ETFs hold Enfusion's stock? ETFs with the largest weight of Enfusion (NYSE:ENFN) stock in their portfolio include Direxion Daily Cloud Computing Bull 2x (CLDL).Ranger Equity Bear ETF (HDGE). What guidance has Enfusion issued on next quarter's earnings? Enfusion issued an update on its FY 2023 earnings guidance on Wednesday, March, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $185.00 million-$190.00 million, compared to the consensus revenue estimate of $188.13 million. When did Enfusion IPO? (ENFN) raised $300 million in an initial public offering (IPO) on Thursday, October 21st 2021. The company issued 18,750,000 shares at a price of $15.00-$17.00 per share. What is Enfusion's stock symbol? Enfusion trades on the New York Stock Exchange (NYSE) under the ticker symbol "ENFN." Who are Enfusion's major shareholders? Enfusion's stock is owned by a variety of retail and institutional investors. Top institutional investors include Alliancebernstein L.P. (0.95%), New York State Common Retirement Fund (0.59%), Geode Capital Management LLC (0.31%), Bank of America Corp DE (0.17%), Franchise Capital Ltd (0.17%) and Charles Schwab Investment Management Inc. (0.12%). Insiders that own company stock include Dan Groman, Hillhouse Investment Managemen, Roy Luo, Stephen Malherbe and Tarek Hammoud. View institutional ownership trends. How do I buy shares of Enfusion? Shares of ENFN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Enfusion's stock price today? One share of ENFN stock can currently be purchased for approximately $10.49. How much money does Enfusion make? Enfusion (NYSE:ENFN) has a market capitalization of $1.21 billion and generates $150.35 million in revenue each year. The company earns $-7,650,000.00 in net income (profit) each year or ($0.10) on an earnings per share basis. How many employees does Enfusion have? The company employs 1,006 workers across the globe. How can I contact Enfusion? The official website for the company is www.enfusion.com. The company can be reached via phone at 312-253-9800 or via email at brian.murphy@icrinc.com. This page (NYSE:ENFN) was last updated on 3/22/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.